Immunovant's Batoclimab Fails Phase 3 Thyroid Eye Disease Trials Despite Early Promise
核心洞察
Immunovant's FcRn (搜索) blocker batoclimab failed to meet primary efficacy endpoints in two Phase 3 trials (GO-1 and GO-2) for thyroid eye disease (搜索), despite showing some improvement in eye bulging symptoms.
The drug demonstrated efficacy during the initial 12-week high-dose stage but missed targets in the subsequent 12-week low-dose phase, supporting the need for deeper IgG (搜索) suppression according to the company.
Immunovant shares declined approximately 6% following the announcement, though the modest impact reflects the company's shifted focus toward its next-generation FcRn (搜索) blocker IMVT-1402.
Immunovant's experimental thyroid eye disease (搜索) treatment batoclimab has failed to achieve its primary efficacy objectives in two pivotal Phase 3 trials, dealing a significant blow to the company's plans to bring the FcRn (搜索) blocker to market for this rare autoimmune condition.
The Roivant (搜索) group company announced that while batoclimab showed some improvement in eye bulging (proptosis) associated with moderate to severe thyroid eye disease (搜索) (TED), it did not meet the primary efficacy endpoints in either the GO-1 or GO-2 studies. The trials evaluated the drug's ability to reduce eye swelling in adults with active thyroid disease.
Mixed Results Across Trial Phases
According to Immunovant, batoclimab demonstrated efficacy during the initial 12-week high-dose stage of the trials but failed to maintain effectiveness in the subsequent 12-week low-dose phase. The company stated that this pattern "supports the benefit of deeper IgG (搜索) suppression," suggesting that more aggressive dosing may be necessary for sustained therapeutic benefit.
The safety profile remained consistent with previous findings, with no new safety signals identified during the studies. However, Immunovant has not yet released detailed efficacy data from the trials.
Strategic Shift to Next-Generation Therapy
The trial failures had a relatively modest impact on Immunovant's stock price, with shares declining approximately 6% following the announcement. This measured market response reflects the company's already-downgraded priority for the batoclimab program, as Immunovant has shifted its focus toward IMVT-1402, a next-generation FcRn (搜索) blocker.
IMVT-1402 offers several potential advantages over batoclimab, including similar potent reductions in IgG (搜索) levels without affecting albumin and LDL cholesterol levels, which should deliver a better benefit-to-risk ratio. The newer drug can also be delivered in lower volumes through subcutaneous injection, potentially making it suitable for self-injection devices.
Competitive Landscape and Future Plans
The thyroid eye disease (搜索) market is currently dominated by Amgen's Tepezza (teprotumumab), the first FDA-approved treatment for TED, which generated revenues of more than $1.9 billion last year. Tepezza is administered intravenously once every three weeks.
Viridian Therapeutics is also advancing in this space with veligrotug, another IGF-1 (搜索) class drug that has been filed with the FDA for TED approval, with a decision expected by June 30. The company is also developing elegrobart (搜索), a subcutaneous IGF-1 drug administered by autoinjector every four to eight weeks, with a US filing expected in early 2027.
Development Pipeline Continues
Despite the batoclimab setback, Immunovant's broader development pipeline remains active. The company expects topline data from Phase 3 studies of IMVT-1402 in Graves' disease (搜索) next year and has completed enrollment in a potentially registrational trial for difficult-to-treat rheumatoid arthritis (搜索), with results possible before year-end.
IMVT-1402 is also being evaluated across multiple autoimmune conditions, including myasthenia gravis (搜索), chronic inflammatory demyelinating polyneuropathy (搜索), Sjögren's disease (搜索), and cutaneous lupus erythematosus (搜索).
Immunovant will now discuss future plans for batoclimab with its development partner HanAll Biopharma (搜索), though further investment in the program from the US company appears unlikely given the strategic pivot to IMVT-1402.